Comprehensive liquid biopsy analysis for monitoring NSCLC patients under second-line osimertinib treatment
Our results reveal that comprehensive liquid biopsy analysis can efficiently represent the heterogeneous molecular landscape and provide prominent information on subsequent treatments for NSCLC patients at PD since druggable molecular alterations were detected in CTCs.
Authors
- Galatea Kallergi (ORCID: https://orcid.org/0000-0001-9825-3871)
- Theodoros Marras
- Aliki Ntzifa (ORCID: https://orcid.org/0000-0002-5598-5447)
- Evi Lianidou (ORCID: https://orcid.org/0000-0002-7796-5914)
- Vassilis Georgoulias (ORCID: https://orcid.org/0000-0003-2218-2522)
- Αthanasios Kotsakis (ORCID: https://orcid.org/0000-0002-5530-6774)
Institutions
- University of Patras (GR)
- National and Kapodistrian University of Athens (GR)
- University Hospital of Larissa (GR)
- Metropolitan Hospital (GR)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2024-10-21
- DOI
- https://doi.org/10.3389/fonc.2024.1435537
- Citations
- 8
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 3.35
Funders
- Stavros Niarchos Foundation
- National and Kapodistrian University of Athens